Janée D. Terwoord

Janée D. Terwoord

Auto-generated profile, based on publicly available information

Janée D. Terwoord

Colorado State University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2023 in Food & Function
Verified
Journal Article
Open access
PDF file
EWEmily K. Woolf
Emily K. Woolf
JTJanée D. Terwoord
Janée D. Terwoord
NLNicole S. Litwin
Nicole S. Litwin
AVAllegra R. Vazquez
Allegra R. Vazquez
SLSylvia Y. Lee
Sylvia Y. Lee
Sarah JohnsonSarah Johnson
Sarah Johnson
This randomized, double-blind, placebo-controlled trial showed that blueberries improve endothelial function through reduced oxidative stress in postmenopausal women with above-normal blood pressure.

1 October 2022 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
Jean C. BikomeyeJean C. Bikomeye
Jean C. Bikomeye
JTJanée D. Terwoord
Janée D. Terwoord
Janine SantosJanine Santos
Janine Santos
Andreas BeyerAndreas Beyer
Andreas Beyer
Many anticancer therapies (CTx) have cardiotoxic side effects that limit their therapeutic potential and cause long-term cardiovascular complications in cancer survivors. This has given rise to the field of cardio-oncology, which recognizes the need for basic, translational, and clinical research focused on understanding the complex signaling events that drive CTx-induced cardiovascular toxicity. Several CTx agents cause mitochondrial damage in the form of mitochondrial DNA deletions, mutations, and suppression of respiratory function and ATP production. In this review, we provide a brief overview of the cardiovascular complications of clinically used CTx agents and discuss current knowledge of local and systemic secondary signaling events that arise in response to mitochondrial stress/damage. Mitochondrial oxidative stress has long been recognized as a contributor to CTx-induced cardiotoxicity; thus, we focus on emerging roles for mitochondria in epigenetic regulation, innate immunity, and signaling via noncoding RNAs and mitochondrial hormones. Because data exploring mitochondrial secondary signaling in the context of cardio-oncology are limited, we also draw upon clinical and preclinical studies, which have examined these pathways in other relevant pathologies.

3 May 2018 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
JTJanée D. Terwoord
Janée D. Terwoord
CHChristopher M. Hearon
Christopher M. Hearon
GLGary J. Luckasen
Gary J. Luckasen
JRJennifer C. Richards
Jennifer C. Richards
MJMichael J. Joyner
Michael J. Joyner
FDFrank A Dinenno
Frank A Dinenno
The increase in interstitial potassium (K+) during muscle contractions is thought to be a vasodilatory signal that contributes to exercise hyperemia. To determine the role of extracellular K+in exercise hyperemia, we perfused skeletal muscle with K+before contractions, such that the effect of any endogenously-released K+would be minimized. We tested the hypothesis that local, intra-arterial infusion of potassium chloride (KCl) at rest would impair vasodilation in response to subsequent rhythmic handgrip exercise in humans. In 11 young adults, we determined forearm blood flow (FBF) (Doppler ultrasound) and forearm vascular conductance (FVC) (FBF/mean arterial pressure) during 4 min of rhythmic handgrip exercise at 10% of maximal voluntary contraction during 1) control conditions, 2) infusion of KCl before the initiation of exercise, and 3) infusion of sodium nitroprusside (SNP) as a control vasodilator. Infusion of KCl or SNP elevated resting FVC similarly before the onset of exercise (control: 39 ± 6 vs. KCl: 81 ± 12 and SNP: 82 ± 13 ml·min−1·100 mmHg−1; both P < 0.05 vs. control). Infusion of KCl at rest diminished the hyperemic (ΔFBF) and vasodilatory (ΔFVC) response to subsequent exercise by 22 ± 5% and 30 ± 5%, respectively (both P < 0.05 vs. control), whereas SNP did not affect the change in FBF ( P = 0.74 vs. control) or FVC ( P = 0.61 vs. control) from rest to steady-state exercise. These findings implicate the K+ion as an essential vasodilator substance contributing to exercise hyperemia in humans.NEW & NOTEWORTHY Our findings support a significant and obligatory role for potassium signaling in the local vasodilatory and hyperemic response to exercise in humans.

30 September 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
JTJanée D. Terwoord
Janée D. Terwoord
LTLaura E. Norwood Toro
Laura E. Norwood Toro
SHShelby N. Hader
Shelby N. Hader
SHStephen T. Hammond
Stephen T. Hammond
JHJoseph C. Hockenberry
Joseph C. Hockenberry
Andreas BeyerAndreas Beyer
Andreas Beyer
BACKGROUND: Cardiotoxicity is a major complication of anticancer therapy (CTx); however, the effect of CTx on the microcirculation is not well defined. This study evaluated the effect of CTx on microvascular function in patients with breast cancer (PwBC). METHODS: Endothelial function and angiogenic potential were assessed in arterioles and adipose biopsies obtained from PwBC undergoing CTx (longitudinal and cross-sectional) and in healthy arterioles exposed to doxorubicin (Dox), trastuzumab (TZM), or paclitaxel (PTX) ex vivo. VEGF-B protein was used to test feasibility of targeted intervention. RESULTS: PwBC treated with Dox and/or TZM developed profound microvascular endothelial dysfunction that persisted for ≥ 9 months after treatment cessation. Angiogenic potential was reduced during CTx and recovered within 1 month. Gene expression related to angiogenesis and inflammation changed over the course of clinical treatment. Adipose arterioles from healthy donors developed endothelial dysfunction when exposed to Dox or TZM ex vivo. PTX, which poses minimal cardiovascular risk, had no effect on vasomotor function. Ex vivo exposure to Dox or PTX suppressed angiogenic potential, whereas TZM had no effect. VEGF-B protein preserved endothelial function in arterioles exposed to Dox or TZM ex vivo. CONCLUSION: PwBC undergoing treatment with Dox and/or TZM develop prolonged microvascular endothelial dysfunction that is recapitulated in healthy arterioles exposed to Dox or TZM ex vivo. Targeted intervention with VEGF-B protects against direct Dox- or TZM-induced vascular toxicity in human arterioles ex vivo. FUNDING: NIH, American Heart Association, WeCare Foundation, Medical College of Wisconsin, Advancing a Healthier Wisconsin, Jenny and Antti Wihuri Foundation.

16 May 2020
Verified
Journal Article
Closed access
PDF file
JTJanée D. Terwoord
Janée D. Terwoord
CJChristopher M. Hearon Jr.
Christopher M. Hearon Jr.
MRMatthew L. Racine
Matthew L. Racine
NKNathaniel B. Ketelhut
Nathaniel B. Ketelhut
GLGary J. Luckasen
Gary J. Luckasen
FDFrank A Dinenno
Frank A Dinenno

24 June 2021 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
JTJanée D. Terwoord
Janée D. Terwoord
MRMatthew L. Racine
Matthew L. Racine
CHChristopher M. Hearon
Christopher M. Hearon
GLGary J. Luckasen
Gary J. Luckasen
FDFrank A Dinenno
Frank A Dinenno
The results of this study highlight the vascular endothelium as a critical site for integration of vasomotor signals in humans. For the first time, to our knowledge, we demonstrate that combined stimulation of the endothelium with ATP and ACh results in enhanced vasodilation compared with combination of either ATP or ACh with an endothelium-independent dilator. Furthermore, we show that ATP and ACh interact to modulate α1-adrenergic vasoconstriction in human skeletal muscle in vivo.